ALBUQUERQUE, N.M., March 21 /PRNewswire/ -- Exagen Diagnostics, Inc., an
emerging leader in the rapid identification and productization of practical,
genomic markers for prognostic testing, today announced that Thomas Williams,
M.D., joined the company as special advisor for molecular pathology. Dr.
Williams will provide Exagen executives with scientific and market-based
counsel on unmet needs in pathology.
Dr. Williams is vice chairman, department of pathology, at the University
of New Mexico School of Medicine. In addition, he serves as director of the
Genetics and Cytometry Division at TriCore Reference Laboratories, a regional
medical laboratory affiliated with the University of New Mexico Health
Sciences Center and Presbyterian Healthcare Services, where he is responsible
for medical direction of the molecular diagnostics laboratory. Dr. Williams
has acted as principal investigator in several cancer-related Human Leukocyte
Antigen (HLA)-focused research studies, and has a special interest in gene
expression work related to hepatitis C discovery and study.
Exagen's first prognostic reagents for breast cancer use small sets of
genes in combination to detect DNA changes, making them more accurate, more
practical and more efficient than any other prognostic test currently
available to guide treatment of breast cancer patients. The company's next set
of prognostic reagents is being developed to identify those patients who may
benefit from standard treatment for hepatitis C and to identify patients at
risk for development of liver cancer.
About Exagen Diagnostics, Inc.
As an emerging leader in prognostic testing, Exagen Diagnostics is
uniquely able to define small sets of genomic markers that are more accurate
than other approaches, whether for breast cancer, infectious disease or other
indications. Exagen's proprietary discovery and implementation technologies
enable the rapid identification and productization of optimized DNA or RNA
genomic marker sets for prognostic or predictive testing, either for
diagnostic testing by reference laboratories or for pharmaceutical R&D
purposes. For more information, visit www.exagendiagnostics.com.
SOURCE Exagen Diagnostics, Inc.